Aimmune Therapeutics

Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc., a Nestlé Health Science company developing and commercializing pharmaceutical therapies to prevent, manage, and treat food and metabolic-related diseases, today presented results from longitudinal analyses evaluating immunological outcomes of long-term daily oral immunotherapy (OIT) with PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] in patients with peanut allergy (PA) for up to 6 years, as well as new data on the util

Aimmune Therapeutics Presents New PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] Data on Immunological Outcomes of Long-Term Daily Oral Immunotherapy at the EAACI PAAM Digital Meeting

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc., a Nestlé Health Science company developing and commercializing pharmaceutical therapies to prevent, manage, and treat food and metabolic-related diseases, today announced it will present new data on the burden of peanut allergy (PA) on patients' and caregivers' Quality of Life. In addition, the company will share results from physician surveys on real-world experiences with PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp]

Aimmune Therapeutics to Present New Data at ACAAI on the Real-World Burden of Peanut Allergy and Early Physician Experience with PALFORZIA® in Clinical Practice in the U.S.

LONDON--(BUSINESS WIRE)--Aimmune Therapeutics UK Ltd., a Nestlé Health Science company developing and commercialising pharmaceutical therapies to prevent, manage, and treat food and metabolic related diseases, today announced it will present new treatment satisfaction data for its oral immunotherapy drug, PALFORZIA, at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2021 in Poland. The company will share updated treatment satisfaction data evaluated in its Phase

Aimmune to Present New Two-Year Treatment Satisfaction Data From Patients With Peanut Allergy at EAACI Hybrid Annual Congress 2021

BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, a Nestlé Health Science company developing and commercializing treatments for potentially life-threatening food allergies, today announced new clinical data from a pooled analysis of three controlled phase 3 (PALISADE1, RAMSES, ARTEMIS2) and three open-label extension (ARC0043, ARC008, ARC011) trials of PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp]. These data will be presented at the American Academy of Allergy, Asthma &amp

Aimmune Presents New Clinical Data From Pooled Safety Analysis in Patients Treated With PALFORZIA® for up to ~3.5 Years

Nestle SA

VEVEY, Switzerland & LONDON--(BUSINESS WIRE)--European Commission Approves Aimmune's PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EU

European Commission Approves Aimmune's PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EU

Apple

Disney

Energy Transfer LP Unit

Freeport-McMoRan

Hercules Capital

Luckin Coffee

PennyMac Financial Services

Roku

Wayfair

Investors don't need a crystal ball to see how major trends in sectors such as e-commerce and biotech are supporting the best stocks in 2020. The post 10 Best Stocks for 2020: Megatrends Support This Year's Biggest Winners appeared first on InvestorPlace.

10 Best Stocks for 2020: Megatrends Support This Year's Biggest Winners

NEW YORK, Oct. 15, 2020 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the Northern District of California, Case No. 4:20-cv-06733-YGR, on behalf of common shareholders of Aimmune...

Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Aimmune Therapeutics, Inc. In The Northern District Of California

Nestlé completes acquisition of Aimmune Therapeutics

Aimmune Therapeutics Inc shareholders have backed Nestle's $2 billion offer to gain full ownership of the first U.S.-approved peanut allergy treatment, which has struggled with a slow launch due to the COVID-19 pandemic.

Aimmune shareholders accept $2 billion Nestle tender offer

Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.

Nestle picked my Best Stocks pick up for a steal, but I believe the decade of biotechnology is just now getting started. The post Best Stocks for 2020: Aimmune Therapeutics Gets Picked Up for a Steal appeared first on InvestorPlace.

Best Stocks for 2020: Aimmune Therapeutics Gets Picked Up for a Steal

AIMT's stock fell precipitously amid the COVID-19 pandemic, despite receiving FDA approval for its Palforzia treatment (the first FDA approved treatment for peanut allergies).

Aimmune Therapeutics: Do Not Tender Your Shares To Nestle

NEW YORK, Sept. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Aimmune Therapeutics, Inc. ("Aimmune" or the "Company") (AIMT)...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics, Inc. - AIMT

Nestlé commences tender offer for Aimmune Therapeutics, Inc.

NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Aimmune Therapeutics, Inc.

Lifshitz Law Firm, P.C. Announces Investigation of Aimmune Therapeutics, Inc.

Nestle is buying the small-cap biotech, and it's paying a high premium.

Why Aimmune Therapeutics Stock Jumped by 159% in August

PHILADELPHIA, Sept. 5, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Aimmune Therapeutics, Inc.

Kaskela Law LLC Announces Stockholder Investigation of Aimmune Therapeutics, Inc. (AIMT) and Encourages Investors to Contact the Firm

These drugmakers are in the sweet spot to provide market-beating returns.

2 Mid-Cap Healthcare Stocks to Buy Now

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

AIMMUNE INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ﻿﻿ Aimmune Therapeutics Inc. - AIMT

Wilmington, Delaware--(Newsfile Corp. - September 1, 2020) -  Rigrodsky & Long, P.A.

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Aimmune Therapeutics, Inc.

Aimmune (AIMT) reaches an agreement with Nestle, S.A wherein the latter will acquire the company in an all-cash transaction worth $2.6 billion. Shares surge.

Aimmune Set to be Acquired by Nestle for $2.6B, Stock Up

Swiss giant adds third drug to its portfolio this year

Nestle Shells Out $2 Billion for Peanut Allergy Med

NEW YORK, Aug. 31, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Aimmune Therapeutics, Inc. ("AIMT" or the "Company") (NASDAQ: AIMT) in connection with the proposed acquisition of the Company by Sociétés des Produits Nestlé S.A. ("Nestlé").  Under the terms of the acquisition agreement, which is structured as a tender offer, the Company's shareholders will receive $34.50 in cash for each share of AIMT common stock that they own.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Aimmune Therapeutics, Inc.

Utz Brands

Stock Markets Celebrate a Strong August; Nestle's Hungry for Aimmune as Utz Feeds IPO Investors

Aimmune Therapeutics' news of its agreement with Nestle regarding its food allergy treatment has AIMT stock soaring way higher on Monday.

News for Aimmune Therapeutics Stock (AIMT)